MAPT and type 2 diabetes mellitus: Notably, in T2DM subjects with Braak stage III–VI, the CP13-ir area was significantly lower than in stage-matched controls, while the AT8- and PHF1-ir areas were significantly higher (Figs. 2a–i), indicating a shift toward more advanced tau pathology in T2DM.